<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="an opportunity of early access to experimental drugs for the" exact="treatment" post="of life-threatening diseases and a potential boon to many"/>
 <result pre="C222 (Erbitux), which was then undergoing clinical trial for the" exact="treatment" post="of colorectal cancer. Due to her ineligibility to participate"/>
 <result pre="including the drug sponsor for potential negative outcomes of the" exact="treatment" post="unless the medical provider and the sponsor were engaged"/>
 <result pre="common among cancer patients and it can potentially affect the" exact="treatment" post="outcome, worsen the adverse effects due to polypharmacy and"/>
 <result pre="limited unless the experimental drug has gone through further rigorous" exact="testing" post="and/or the experimental drug is paired synergistically with an"/>
 <result pre="panomics in personalizing medicine are emerging and promising in the" exact="treatment" post="of diseases such as cancer, cardiovascular and gastrointestinal disorders"/>
 <result pre="[20, 21]. While panomics addresses many of the precision medicine" exact="treatment" post="benefits, it falls short in addressing issues such as"/>
 <result pre="impact on drug development, clinical trials and in personalizing the" exact="treatment" post="for therapeutic efficacy, maximum safety, higher durable response, longevity"/>
 <result pre="2 negative (HER2âˆ’) advanced or metastatic breast cancer, for the" exact="treatment" post="of breast cancer in men [27, 28]. The former"/>
 <result pre="Institutes of Health (NIH), the NCI-MATCH, a precision medicine cancer" exact="treatment" post="clinical trial that is co-led by National Cancer Institute"/>
 <result pre="the results from Arm H of the study demonstrated that" exact="treatment" post="with a â€œcocktailâ€� of dabrafenib and trametinib, designed to"/>
 <result pre="in reviewing the consent procedures. The positive outcome of the" exact="treatment" post="results will thus be a potential boon to young"/>
 <result pre="personalized medicine, data refineries, artificial intelligence and machine learning, further" exact="testing" post="of drugs, including adjuvant therapies or â€œcocktailâ€� of drugs"/>
 <result pre="Health Council (GHC) over the last few decades for the" exact="treatment" post="of diseases, patient and public engagements, the role of"/>
 <result pre="and many challenges for the â€œRight-to-Tryâ€� experimental drugs for the" exact="treatment" post="of life-threatening diseases. The â€œRight-to-Tryâ€� experimental drug is nevertheless"/>
</results>
